Table 1.
Study design and clinical characteristics.
| Study Design Details | Clinical Characteristics | ||||||
|---|---|---|---|---|---|---|---|
| Patient | Workflow | Sample Subset | Age | FIGO Stage | Debulking Surgery * | Residual Disease | Progression-Free Survival (PFS) |
| 1 |
NGS & dPCR: TP53 only |
Tissue & longitudinal cfDNA | 43 | IV | PDS | 0–1 cm | >6 months |
| 2 | 37 | IIIC | PDS | 1 cm or more | >6 months | ||
| 3 | 69 | IIIC | PDS | 1 cm or more | >6 months | ||
| 4 | 56 | IV | PDS | 0–1 cm | >6 months | ||
| 5 | 73 | IIIC | IDS | 0–1 cm | >6 months | ||
| 6 ** | 53 | IIIC | PDS | 0–1 cm | >6 months | ||
| 7 | 58 | IV | PDS | 1 cm or more | >6 months | ||
| 8 | 58 | IIIC | PDS | 0–1 cm | >6 months | ||
| 9 | 72 | IIIC | IDS | 1 cm or more | >6 months | ||
| 10 ** | 75 | IV | IDS | 1 cm or more | >6 months | ||
| 11 |
NGS only: Multigene panels including TP53 |
Tissue & baseline cfDNA | 47 | IV | IDS | 0–1 cm | >6 months |
| 12 | 47 | IIIC | IDS | 0–1 cm | >6 months | ||
| 13 | 57 | IIIC | IDS | 0–1 cm | >6 months | ||
| 14 | 49 | IC | PDS | 0–1 cm | >6 months | ||
| 15 | 61 | IV | IDS | 0–1 cm | >6 months | ||
| 16 | 63 | IIIC | IDS | 0–1 cm | 0–6 months | ||
| 17 | 45 | IV | IDS | 0–1 cm | 0–6 months | ||
| 18 ** | 65 | IV | NA * | 1 cm or more | 0–6 months | ||
| 19 | 47 | IV | NA * | 1 cm or more | 0–6 months | ||
| 20 | 72 | IV | IDS | 1 cm or more | 0–6 months | ||
* PDS = primary Debulking surgery, IDS = interval Debulking surgery, NA = not available. ** Patients were excluded from cfDNA analysis because their tissue had no TP53 missense mutations.